Alteration of nucleotide metabolism: A new mechanism for mitochondrial disorders

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 7, 2003, Pages 845-851

  Martí, Ramon ^a   Nishigaki, Yutaka ^a   Vilá, Maya R ^a   Hirano, Michio ^a  

^a Columbia Univ of Coll Phys/Surg ^*  (United States)

Author keywords

Depletion; Mitochondria; Mitochondrial neurogastrointerstinal encephalomyopathy; MNGIE; Nucleoside; Nucleotide

Indexed keywords

2' DEOXYNUCLEOSIDE; ADENINE NUCLEOTIDE TRANSLOCASE; DEOXYGUANOSINE KINASE; DEOXYURIDINE; ISOENZYME; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; THYMIDINE; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE;

AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; CELL NUCLEUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENCEPHALOMYOPATHY; ENZYME DEFICIENCY; GENE DELETION; GENE MUTATION; GENETIC CODE; HUMAN; MICROCEPHALY; NUCLEOTIDE METABOLISM; OPHTHALMOPLEGIA; PATHOPHYSIOLOGY; POINT MUTATION; PRIORITY JOURNAL; REVIEW;

DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIAL MYOPATHIES; RIBONUCLEOTIDES; THYMIDINE PHOSPHORYLASE;

EID: 0042474390     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.128     Document Type: Review

References (59)

1. Anderson S, Bankier A, Barrell B. Sequence and organization of the human mitochondrial genome. Nature 1981; 290:457-65.
2. Hirano M, Marti R, Ferreiro-Barros C, Vilb MR, Taclesse S, Nishigaki Y, et al. Defects of intergenomic communication: autosomal disorders that cause multiple deletions and depletion of mitochondrial DNA. Semin Cell Biol Develop 2001; 12:417-27.
3. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999; 283:689-92.
4. Kaukonen J, Juselius JK, Tiranti V, Kyttala A, Zeviani M, Comi GP, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 2000; 289:782-5.
5. Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 2001; 29:342-4.
6. Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 2001; 29:337-41.
7. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. New Engl J Med 1990; 322:1098-105.
8. Hirano M, Silvestri G, Blake DM, Lombes A, Minetti C, Bonilla E, et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology 1994; 44:721-7.
9. Papadimitriou A, Comi GP, Hadjigeorgiou GM, Bordoni A, Sciacco M, Napoli L, et al. Partial depletion and multiple deletions of muscle mtDNA in familial MNGIE syndrome. Neurology 1998; 51:1086-92.
10. Nishino I, Spinazzola A, Papadimitriou A, Hammans S, Steiner I, Hahn CID, et al. MNGIE: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 2000; 47:792-800.
11. Bardosi A, Creutzfeldt W, DiMauro S, Felgenhauer K, Friede RL, Goebel HH, et al. Myo-, neuro-, gastrointestinal encephalopathy (MNGIE syndrome) due to partial deficiency of cytochrome-c-oxidase. A new mitochondrial multisystem disorder. Acta Neuropathol (Berl) 1987; 74:248-58.
12. Simon LT, Horoupian IDS, Dorfman LJ, Marks M, Herrick MK, Wasserstein P, et al. Polyneuropathy, ophthalmoplegia, leukoencephalopathy and intestinal pseudo-obstruction: POLIP syndrome. Ann Neurol 1990; 28:349-60.
13. Lowsky R, Davidson G, Wolman S, Jeejeebhoy KN, Hegele RA. Familial visceral myopathy associated with a mitochondrial myopathy. Gut 1993; 34:279-83.
14. Nishigaki Y, Marti R, Copeland WC, Hirano M. Sitespecific mitochondrial DNA point mutations in patientswith thymidine phosphorylase deficiency. J Clin Invest 2003. In press.
15. Hirano M, Yebenes J, Jones AC, Nishino I, DiMauro S, Carlo JR, et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) syndrome maps to chromosome 22q13.32-qter. Am J Hum Genet 1998; 63:526-33.
16. Hagiwara K, Stenman G, Honda H, Sahlin P, Andersson A, Miyazono K, et al. Organization and chromosomal localization of the human platelet-derived endothelial cell growth factor gene. Mol Cell Biol 1991; 11:2125-32.
17. Brown NS, Bicknell R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 1998; 334:1-8.
18. Usuki K, Saras J, Waltenberger J, Miyazono K, Pierce G, Thomason A, et al. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun 1992; 184:1311-6.
19. Asai K, Hirano T, Kaneko S, Moriyama A, Nananishi K, lsobe I, et al. A novel glial growth inhibitory factor, gliostatin, derived from neurofibroma. J Neurochem 1992a; 59:307-17.
20. Focher F, Spadari S. Thymidine phosphorylase: a two-faced Janus in anticancer chemotherapy. Current Cancer Drug Targets 2001; 1:139-51.
21. Desgranges C, Razaka G, Rabaud M, Bricaud H. Catabolism of thymidine in human blood platelets: purification and properties of thymidine phosphorylase. Biochim Biophys Acta 1981; 654:211-8.
22. Kono A, Hara Y, Sugata S, Matsushima Y, Ueda T. Substrate specificity of a thymidine phosphorylase in human liver tumor. Chem Pharm Bull (Tokyo) 1984; 32:1919-21.
23. el Kouni MH, el Kouni MM, Naguib FN. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: implications for chemotherapy with 5-fluoropyrimidines. Cancer Res 1993; 53:3687-93.
24. Yoshimura A, Kuwazuru Y, Furukawa T, Yoshida H, Yamada K, Akiyama S. Purification and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors. Biochim Biophys Acta 1990; 1034:107-13.
25. Waltenberger J, Usuki K, Fellstrom B, Funa K, Heldin CH. Platelet-derived endothelial cell growth factor. Pharmaco-kinetics, organ distribution and degradation after intravenous administration in rats. FEBS Lett 1992; 313:129-32.
26. Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissue: an immunohistochemical study. J Pathol 1995; 176: 183-90.
27. Eccleston PA, Funa K, Heldin CH. Neurons of the peripheral nervous system express thymidine phosphorylase. Neurosci Lett 1995; 192:137-41.
28. Matsukawa K, Moriyama A, Kawai Y, Asai K, Kato T. Tissue distribution of human gliostatin/platelet-derived endothelial cell growth factor (PD-ECGF) and its drug-induced expression. Biochim Biophys Acta 1996; 1314:71-82.
29. Griffiths L, Stratford IJ. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer 1997; 76:689-93.
30. Spinazzola A, Marti R, Nishino 1, Andreu A, Nainj A, Tadesse S, et al. Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem 2002; 277: 4128-33.
31. Marti, Nishigaki Y, Hirano M. Elevated plasma deoxyuridine in patients with thymidine phosphorylase deficiency. Biochem Biophys Res Commun 2003; 303:14-8.
32. Gutierrez MM, Brett CM, Ott RJ, Hui AC, Giancomini KM. Nucleoside transport in brush border membrane vesicles from human kidney. Biochim Biophys Acta 1992; 1105:1-9.
33. Gutierrez MM, Giacomini KM. Substrate selectivity, potential sensitivity and stoichiometry of Na(+)- nucleoside transport in brush border membrane vesicles from human kidney. Biochim Biophys Acta 1993; 1149:202-8.
34. Crawford CR, Patel DH, Naeve C, Belt JA. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J Biol Chem 1998; 273:5288-93.
35. Van Aubel RA, Masereeuw R, Russel FG. Molecular pharmacology of renal organic anion transporters. Am J Physiol Renal Physiol 2000; 279:F216-32.
36. Elpeleg O, Mandel H, Saada A. Depletion of the other genome-mitochondrial [DNA depletion syndromes in humans. J Mol Med 2002; 80:389-96.
37. Bogenhagen D, Clayton DA. Thymidylate nucleotide supply for mitochondrial DNA synthesis in mouse L-cells. J Biol Chem 1976; 249:2938-44.
38. Bestwick RK, Mathews CK. Unusual compartment of precursors for nuclear and mitochondrial DNA in mouse L cells. J Biol Chem 1982; 257:9305-8.
39. Bestwick RK, Moffett GL, Mathews CK. Selective expansion of mitochondrial nucleoside triphosphate pools in anti meta bo I ite-treated HeLa cells. J Biol Chem 1982; 257: 9300-4.
40. Arnér ESJ, Eriksson S. Mammalian deoxynucleoside kinases. Pharmacol Ther 1995; 67:155-86.
41. Ladner RD, Caradonna SJ. The human dUTPase gene encodes both nuclear and mitochondrial isoforms. Differential expression of the isoforms and characterization of a cDNA encoding the mitochondrial species. J Biol Chem 1997; 272:19072-80.
42. Richards RG, Sowers LC, Laszlo J, Sedwick WD. The occurrence and consequences of deoxyuridine in DNA. Adv Enzyme Regul 1984; 22:157-85.
43. Tomilin NV, Aprelikova ON. Uracil-DNA glycosylases and DNA uracil repair. Int Rev Cytol 1989; 114:125-79.
44. Goulian M, Bleile B, Tseng BY. Methotrexate-induced misincorporation of uracil into DNA. Proc Natl Aced Sci USA 1980; 77:1956-60.
45. Melnyk S, Pogribna M, Miller BJ, Basnakian AG, Pogribny IP, James SJ. Uracil misincorporation, DNA strand breaks, and gene amplification are associated with tumorigenic cell transformation in folate deficient/repleted Chinese hamster ovary cells. Cancer Lett 1999; 146:35-44.
46. Sedwick WD, Kutler M, Brown OE. Antifolate-induced misincorporation of deoxyuridine monophosphate into DNA: inhibition of high molecular weight DNA synthesis in human lymphoblastoid cells. Proc Natl Acad Sci USA 1981; 78:917-21.
47. Kunkel TA, Alexander PS. The base substitution fidelity of eucaryotic DNA polymerases. Mispairing frequencies, site preferences, insertion preferences, and base substitution by dislocation. J Biol Chem 1986; 261:160-6.
48. Longley MJ, Nguyen D, Kunkel TA, Copeland WC. The fidelity of human DNA polymerase gamma with and without exonucleolytic proofreading and the p55 accessory subunit. J Biol Chem 2001; 276:38555-62.
49. Eriksson S, Kierdaszuk B, Munch-Petersen B, Oberg B, Johansson NG. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 1991; 176:586-92.
50. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991; 266:9032-8.
51. Young P, Leeds JM, Slabaugh MB, Mathews CK. Ribonucleotide reductase: evidence for specific association with HeLa cell mitochondria. Biochem Biophys Res Commun 1994; 203:46-52.
52. Spelbrink JN, Li FY, Tiranti V, Nikali K, Yuan QP, Tariq M, et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 2001; 28:223-31.
53. Van Goethem G, Dermaut B, Lofgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001; 28:211-2.
54. Rosenberg MJ, Agarwala R, Bouffard G, Davis J, Fiermonte G, Hilliard MS, et al. Mutant deoxynucleotide carrier is associated with congenital microcephaly. Nat Genet 2002; 32:175-9.
55. Dolce V, Fiermonte G, Runswick MJ, Palmieri F, Walker JE. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci USA 2001; 98:2284-8.
56. Arnaudo E, Dalakas MC, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337:508-10.
57. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nature Med 1995; 1:417-22.
58. Brahams D. Deaths in US fialuridine trial. Lancet 1994; 343:1494-5.
59. Cui L, Toon S, Shininazi RF, Sommadossi J-P. Cellular and molecular events leading to mitochondrial toxicity of 1-[2′- deoxy-2′fluoro-p-D-arabinofuranosyl]-5-iodouracil in human liver cells. J Clin Invest 1995; 95:555-63.